Clinical Trial Update: Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma [Phase 2]

View source ↗

Summary

This update describes a Phase 2 trial evaluating durvalumab, bevacizumab, tremelimumab plus transarterial chemoembolization for hepatocellular carcinoma or bili…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma
• Hepatocellular Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Hepatocellular Cancer, Hepatocellular Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING